UBS Raises Biogen Price Target to $300 From $270, Maintains Buy
UBS maintained its Buy rating on Biogen and raised its price target to $300 from $270, an 11.1% increase. The target implies 22.9% upside from the Oct. 28 close of $244.05.
Related stories
Intel Shares Fall 25.4% After Weak Q4 Guidance
Intel forecast fourth-quarter adjusted EPS of 25 cents versus the 43-cent analyst estimate, and revenue of $15 billion to $16 billion versus $17.05 billion expected. Shares fell 25
H impact | EQUITY | Oct 30, 2026, 10:39 AM UTC
Intel Shares Fall About 25% Premarket After Results
Intel shares were down roughly 25% before the bell after the company posted results after hours yesterday. The move could erase around $120 billion from its market value.
H impact | EQUITY | Oct 30, 2026, 10:38 AM UTC
Cameco Reports Third-Quarter Results; Declares Annual Dividend
Cameco reported third-quarter results and declared an annual dividend. The supplied text provides no financial figures or dividend terms.
M impact | EQUITY | Oct 30, 2026, 10:32 AM UTC
TXNM Energy Reports Q3 Results and Updates Blackstone Deal Timing
TXNM Energy said Q3 2026 EPS was reduced by share issuances and transaction costs. Hearings on its Blackstone sale are set for Jan. 19–Feb. 1, 2027, with closing expected in H1 202
H impact | EQUITY | Oct 30, 2026, 10:31 AM UTC
Ingersoll Rand Appoints Segment Leaders and Extends CEO Agreement
Ingersoll Rand appointed Scott Watson to lead IT&S North America and EMEIA, and Shaun Carlson to lead P&ST. Its board approved a new employment agreement with CEO Vicente Reynal.
M impact | EQUITY | Oct 30, 2026, 10:30 AM UTC
ExxonMobil Announces Third-Quarter 2026 Results
M impact | EQUITY | Oct 30, 2026, 10:30 AM UTC